ACA ruling threatens biosimilars provisions

A federal district court ruling Friday that could strike down the entire Affordable Care Act threatens to unravel FDA's biosimilar approval pathway.

The Biologics Price Competition and Innovation

Read the full 277 word article

User Sign In